Liang-zhen You , Qian-qian Dai , Xiao-ying Zhong , Dong-dong Yu , He-rong Cui , Yi-fan Kong , Meng-zhu Zhao , Xin-yi Zhang , Qian-qian Xu , Zhi-yue Guan , Xu-xu Wei , Xue-cheng Zhang , Song-jie Han , Wen-jing Liu , Zhao Chen , Xiao-yu Zhang , Chen Zhao , Ying-hui Jin , Hong-cai Shang
{"title":"三种中药和三种中药配方治疗新冠肺炎的临床证据：中国人群的系统回顾和荟萃分析。","authors":"Liang-zhen You , Qian-qian Dai , Xiao-ying Zhong , Dong-dong Yu , He-rong Cui , Yi-fan Kong , Meng-zhu Zhao , Xin-yi Zhang , Qian-qian Xu , Zhi-yue Guan , Xu-xu Wei , Xue-cheng Zhang , Song-jie Han , Wen-jing Liu , Zhao Chen , Xiao-yu Zhang , Chen Zhao , Ying-hui Jin , Hong-cai Shang","doi":"10.1016/j.joim.2023.08.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The coronavirus disease 2019 (COVID-19) continues to spread worldwide. Integrated Chinese and Western medicine have had some successes in treating COVID-19.</p></div><div><h3>Objective</h3><p><span>This study aims to evaluate the efficacy and safety of three traditional Chinese medicine </span>drugs<span> and three herbal formulas (3-drugs-3-formulas) in patients with COVID-19.</span></p></div><div><h3>Search strategy</h3><p>Relevant studies were identified from 12 electronic databases searched from their establishment to April 7, 2022.</p></div><div><h3>Inclusion criteria</h3><p>Randomized controlled trials<span> (RCTs), non-RCTs and cohort studies<span> that evaluated the effects of 3-drugs-3-formulas for COVID-19. The treatment group was treated with one of the 3-drugs-3-formulas plus conventional treatment. The control group was treated with conventional treatment.</span></span></p></div><div><h3>Data extraction and analysis</h3><p>Two evaluators screened and selected literature independently, then extracted basic information and assessed risk of bias. The treatment outcome measures were duration of main symptoms, hospitalization time, aggravation rate and mortality. RevMan 5.4 was used to analyze the pooled results reported as mean difference (MD) with 95% confidence interval (CI) for continuous data and risk ratio (RR) with 95% CI for dichotomous data.</p></div><div><h3>Results</h3><p>Forty-one studies with a total of 13,260 participants were identified. Our analysis suggests that compared with conventional treatment, the combination of 3-drugs-3-formulas might shorten duration of fever (MD = –1.39; 95% CI: –2.19 to –0.59; <em>P</em> < 0.05), cough (MD = –1.57; 95% CI: –2.16 to –0.98; <em>P</em> < 0.05) and fatigue (MD = –1.36; 95% CI: –2.21 to –0.51; <em>P</em> < 0.05), decrease length of hospital stay (MD = –2.62; 95% CI –3.52 to –1.72; <em>P</em><span> < 0.05), the time for nucleic acid conversion (MD = –2.92; 95% CI: –4.26 to –1.59; </span><em>P</em> < 0.05), aggravation rate (RR = 0.49; 95% CI: 0.38 to 0.64; <em>P</em> < 0.05) and mortality (RR = 0.34; 95% CI: 0.19 to 0.62; <em>P</em><span> < 0.05), and increase the recovery rate of chest computerized tomography manifestations (RR = 1.22; 95% CI: 1.14 to 1.3; </span><em>P</em> < 0.05) and total effectiveness (RR = 1.24; 95% CI: 1.09 to 1.42; <em>P</em> < 0.05).</p></div><div><h3>Conclusion</h3><p>The 3-drugs-3-formulas can play an active role in treating all stages of COVID-19. No severe adverse events related to 3-drugs-3-formulas were observed. Hence, 3-drugs-3-formulas combined with conventional therapies have effective therapeutic value for COVID-19 patients. Further long-term high-quality studies are essential to demonstrate the clinical benefits of each formula.<br></p><p><span>Please cite this article as: You LZ, Dai QQ, Zhong XY, Yu DD, Cui HR, Kong YF, Zhao MZ, Zhang XY, Xu QQ, Guan ZY, Wei XX, Zhang XC, Han SJ, Liu WJ, Chen Z, Zhang XY, Zhao C, Jin YH, Shang HC. Clinical evidence of three traditional Chinese medicine drugs and three herbal formulas for COVID-19: A systematic review and meta-analysis of the Chinese population. </span><em>J Integr Med</em>. 2023; 21(5): 441–454.</p></div>","PeriodicalId":48599,"journal":{"name":"Journal of Integrative Medicine-Jim","volume":"21 5","pages":"Pages 441-454"},"PeriodicalIF":4.2000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical evidence of three traditional Chinese medicine drugs and three herbal formulas for COVID-19: A systematic review and meta-analysis of the Chinese population\",\"authors\":\"Liang-zhen You , Qian-qian Dai , Xiao-ying Zhong , Dong-dong Yu , He-rong Cui , Yi-fan Kong , Meng-zhu Zhao , Xin-yi Zhang , Qian-qian Xu , Zhi-yue Guan , Xu-xu Wei , Xue-cheng Zhang , Song-jie Han , Wen-jing Liu , Zhao Chen , Xiao-yu Zhang , Chen Zhao , Ying-hui Jin , Hong-cai Shang\",\"doi\":\"10.1016/j.joim.2023.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The coronavirus disease 2019 (COVID-19) continues to spread worldwide. Integrated Chinese and Western medicine have had some successes in treating COVID-19.</p></div><div><h3>Objective</h3><p><span>This study aims to evaluate the efficacy and safety of three traditional Chinese medicine </span>drugs<span> and three herbal formulas (3-drugs-3-formulas) in patients with COVID-19.</span></p></div><div><h3>Search strategy</h3><p>Relevant studies were identified from 12 electronic databases searched from their establishment to April 7, 2022.</p></div><div><h3>Inclusion criteria</h3><p>Randomized controlled trials<span> (RCTs), non-RCTs and cohort studies<span> that evaluated the effects of 3-drugs-3-formulas for COVID-19. The treatment group was treated with one of the 3-drugs-3-formulas plus conventional treatment. The control group was treated with conventional treatment.</span></span></p></div><div><h3>Data extraction and analysis</h3><p>Two evaluators screened and selected literature independently, then extracted basic information and assessed risk of bias. The treatment outcome measures were duration of main symptoms, hospitalization time, aggravation rate and mortality. RevMan 5.4 was used to analyze the pooled results reported as mean difference (MD) with 95% confidence interval (CI) for continuous data and risk ratio (RR) with 95% CI for dichotomous data.</p></div><div><h3>Results</h3><p>Forty-one studies with a total of 13,260 participants were identified. Our analysis suggests that compared with conventional treatment, the combination of 3-drugs-3-formulas might shorten duration of fever (MD = –1.39; 95% CI: –2.19 to –0.59; <em>P</em> < 0.05), cough (MD = –1.57; 95% CI: –2.16 to –0.98; <em>P</em> < 0.05) and fatigue (MD = –1.36; 95% CI: –2.21 to –0.51; <em>P</em> < 0.05), decrease length of hospital stay (MD = –2.62; 95% CI –3.52 to –1.72; <em>P</em><span> < 0.05), the time for nucleic acid conversion (MD = –2.92; 95% CI: –4.26 to –1.59; </span><em>P</em> < 0.05), aggravation rate (RR = 0.49; 95% CI: 0.38 to 0.64; <em>P</em> < 0.05) and mortality (RR = 0.34; 95% CI: 0.19 to 0.62; <em>P</em><span> < 0.05), and increase the recovery rate of chest computerized tomography manifestations (RR = 1.22; 95% CI: 1.14 to 1.3; </span><em>P</em> < 0.05) and total effectiveness (RR = 1.24; 95% CI: 1.09 to 1.42; <em>P</em> < 0.05).</p></div><div><h3>Conclusion</h3><p>The 3-drugs-3-formulas can play an active role in treating all stages of COVID-19. No severe adverse events related to 3-drugs-3-formulas were observed. Hence, 3-drugs-3-formulas combined with conventional therapies have effective therapeutic value for COVID-19 patients. Further long-term high-quality studies are essential to demonstrate the clinical benefits of each formula.<br></p><p><span>Please cite this article as: You LZ, Dai QQ, Zhong XY, Yu DD, Cui HR, Kong YF, Zhao MZ, Zhang XY, Xu QQ, Guan ZY, Wei XX, Zhang XC, Han SJ, Liu WJ, Chen Z, Zhang XY, Zhao C, Jin YH, Shang HC. Clinical evidence of three traditional Chinese medicine drugs and three herbal formulas for COVID-19: A systematic review and meta-analysis of the Chinese population. </span><em>J Integr Med</em>. 2023; 21(5): 441–454.</p></div>\",\"PeriodicalId\":48599,\"journal\":{\"name\":\"Journal of Integrative Medicine-Jim\",\"volume\":\"21 5\",\"pages\":\"Pages 441-454\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Integrative Medicine-Jim\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2095496423000638\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Integrative Medicine-Jim","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2095496423000638","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
Clinical evidence of three traditional Chinese medicine drugs and three herbal formulas for COVID-19: A systematic review and meta-analysis of the Chinese population
Background
The coronavirus disease 2019 (COVID-19) continues to spread worldwide. Integrated Chinese and Western medicine have had some successes in treating COVID-19.
Objective
This study aims to evaluate the efficacy and safety of three traditional Chinese medicine drugs and three herbal formulas (3-drugs-3-formulas) in patients with COVID-19.
Search strategy
Relevant studies were identified from 12 electronic databases searched from their establishment to April 7, 2022.
Inclusion criteria
Randomized controlled trials (RCTs), non-RCTs and cohort studies that evaluated the effects of 3-drugs-3-formulas for COVID-19. The treatment group was treated with one of the 3-drugs-3-formulas plus conventional treatment. The control group was treated with conventional treatment.
Data extraction and analysis
Two evaluators screened and selected literature independently, then extracted basic information and assessed risk of bias. The treatment outcome measures were duration of main symptoms, hospitalization time, aggravation rate and mortality. RevMan 5.4 was used to analyze the pooled results reported as mean difference (MD) with 95% confidence interval (CI) for continuous data and risk ratio (RR) with 95% CI for dichotomous data.
Results
Forty-one studies with a total of 13,260 participants were identified. Our analysis suggests that compared with conventional treatment, the combination of 3-drugs-3-formulas might shorten duration of fever (MD = –1.39; 95% CI: –2.19 to –0.59; P < 0.05), cough (MD = –1.57; 95% CI: –2.16 to –0.98; P < 0.05) and fatigue (MD = –1.36; 95% CI: –2.21 to –0.51; P < 0.05), decrease length of hospital stay (MD = –2.62; 95% CI –3.52 to –1.72; P < 0.05), the time for nucleic acid conversion (MD = –2.92; 95% CI: –4.26 to –1.59; P < 0.05), aggravation rate (RR = 0.49; 95% CI: 0.38 to 0.64; P < 0.05) and mortality (RR = 0.34; 95% CI: 0.19 to 0.62; P < 0.05), and increase the recovery rate of chest computerized tomography manifestations (RR = 1.22; 95% CI: 1.14 to 1.3; P < 0.05) and total effectiveness (RR = 1.24; 95% CI: 1.09 to 1.42; P < 0.05).
Conclusion
The 3-drugs-3-formulas can play an active role in treating all stages of COVID-19. No severe adverse events related to 3-drugs-3-formulas were observed. Hence, 3-drugs-3-formulas combined with conventional therapies have effective therapeutic value for COVID-19 patients. Further long-term high-quality studies are essential to demonstrate the clinical benefits of each formula.
Please cite this article as: You LZ, Dai QQ, Zhong XY, Yu DD, Cui HR, Kong YF, Zhao MZ, Zhang XY, Xu QQ, Guan ZY, Wei XX, Zhang XC, Han SJ, Liu WJ, Chen Z, Zhang XY, Zhao C, Jin YH, Shang HC. Clinical evidence of three traditional Chinese medicine drugs and three herbal formulas for COVID-19: A systematic review and meta-analysis of the Chinese population. J Integr Med. 2023; 21(5): 441–454.
期刊介绍：
The predecessor of JIM is the Journal of Chinese Integrative Medicine (Zhong Xi Yi Jie He Xue Bao). With this new, English-language publication, we are committed to make JIM an international platform for publishing high-quality papers on complementary and alternative medicine (CAM) and an open forum in which the different professions and international scholarly communities can exchange views, share research and their clinical experience, discuss CAM education, and confer about issues and problems in our various disciplines and in CAM as a whole in order to promote integrative medicine.
JIM is indexed/abstracted in: MEDLINE/PubMed, ScienceDirect, Emerging Sources Citation Index (ESCI), Scopus, Embase, Chemical Abstracts (CA), CAB Abstracts, EBSCO, WPRIM, JST China, Chinese Science Citation Database (CSCD), and China National Knowledge Infrastructure (CNKI).
JIM Editorial Office uses ThomsonReuters ScholarOne Manuscripts as submitting and review system (submission link: http://mc03.manuscriptcentral.com/jcim-en).
JIM is published bimonthly. Manuscripts submitted to JIM should be written in English. Article types include but are not limited to randomized controlled and pragmatic trials, translational and patient-centered effectiveness outcome studies, case series and reports, clinical trial protocols, preclinical and basic science studies, systematic reviews and meta-analyses, papers on methodology and CAM history or education, conference proceedings, editorials, commentaries, short communications, book reviews, and letters to the editor.
Our purpose is to publish a prestigious international journal for studies in integrative medicine. To achieve this aim, we seek to publish high-quality papers on any aspects of integrative medicine, such as acupuncture and traditional Chinese medicine, Ayurveda medicine, herbal medicine, homeopathy, nutrition, chiropractic, mind-body medicine, taichi, qigong, meditation, and any other modalities of CAM; our commitment to international scope ensures that research and progress from all regions of the world are widely covered. These ensure that articles published in JIM have the maximum exposure to the international scholarly community.
JIM can help its authors let their papers reach the widest possible range of readers, and let all those who share an interest in their research field be concerned with their study.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
